Risk-benefit assessment of drugs used for the treatment of menstrual disorders.
This article considers the benign yet debilitating conditions of menorrhagia, dysmenorrhoea and irregular menstrual bleeding. Surprisingly little has been reported in the literature concerning these common ailments which can detract from the quality of female life during the reproduction years. Both dysmenorrhoea and menorrhagia are subjective complaints, but despite accurate means of measuring menstrual blood loss such quantification is rarely performed. This lack of diagnostic accuracy is a cause for concern, especially as both medical and surgical treatment are not without risk. The therapeutic alternatives which are commonly prescribed in an attempt to rectify such menstrual disorders are discussed. These include the nonsteroidal anti-inflammatory agents, the combined oral contraceptives, danazol, progestogens, antifibrinolytics, haemostatics, luteinising hormone releasing hormone analogues and clomiphene. The results of clinical trials which have utilised these various agents are considered in terms of both the effectiveness of treatment and its potential adverse effects.
Higham
J M
JM
Department of Academic Obstretrics and Gynaecology, Royal Free Hospital, London, England.
Shaw
R W
RW
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D011307:Drug Prescriptions / Q000191:economics; D004979:Ethamsylate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000188:drug therapy*; D011372:Progestins / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003277:Contraceptives, Oral, Combined; D011372:Progestins; D004979:Ethamsylate; D014148:Tranexamic Acid